Research ArticleClinical Review

Non-Surgical Management of Urinary Incontinence

Ranna Al-Dossari, Monica Kalra, Julie Adkison and Bich-May Nguyen
The Journal of the American Board of Family Medicine September 2024, 37 (5) 909-918; DOI: https://doi.org/10.3122/jabfm.2023.230471R1

References

  1. 1.↵
    1. Tran LN,
    2. Puckett Y
    . Urinary incontinence. In: StatPearls. StatPearls Publishing; 2022. Accessed February 28, 2023. http://www.ncbi.nlm.nih.gov/books/NBK559095/.
  2. 2.↵
    1. Gormley EA,
    2. Lightner DJ,
    3. Burgio KL
    , Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstructionet al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol . 2012;188:2455–63.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Burgio KL,
    2. Kraus SR,
    3. Johnson TM,
    4. et al
    . Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med 2020;180:411–9.
    OpenUrlPubMed
  4. 4.↵
    1. Carlson K,
    2. Civitarese A,
    3. Baverstock R
    . OnabotulinumtoxinA for the treatment of idiopathic overactive bladder is effective and safe for repeated use. Can Urol Assoc J 2017;11:E179–E183.
    OpenUrlPubMed
  5. 5.↵
    1. Eldred-Evans D,
    2. Sahai A
    . Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol 2017;9:3–10.
    OpenUrlPubMed
  6. 6.↵
    1. Szymański JK,
    2. Słabuszewska-Jóźwiak A,
    3. Zaręba K,
    4. Jakiel G
    . Neuromodulation - a therapeutic option for refractory overactive bladder. A recent literature review. Wideochir Inne Tech Maloinwazyjne 2019;14:476–85.
    OpenUrlPubMed
  7. 7.↵
    1. Xia L,
    2. Yan H,
    3. Sun Y,
    4. et al
    . Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome. Medicine (Baltimore) 2021;100:e27745.
    OpenUrlPubMed
  8. 8.↵
    1. Charalampous I,
    2. Tailor VK,
    3. Digesu A
    . Vaginal laser for overactive bladder syndrome. Int Urogynecol J 2020;31:1515–7.
    OpenUrlPubMed
  9. 9.↵
    1. Hafidh B,
    2. Baradwan S,
    3. Latifah HM,
    4. et al
    . CO 2 laser therapy for management of stress urinary incontinence in women: a systematic review and meta-analysis. Ther Adv Urol 2023;15:17562872231210216.
    OpenUrlPubMed
  10. 10.↵
    1. Hargreaves E,
    2. Baker K,
    3. Barry G,
    4. et al
    . Acupuncture for treating overactive bladder in adults. Cochrane Database Syst Rev 2022;9:CD013519.
    OpenUrlPubMed
  11. 11.↵
    1. Stoniute A,
    2. Madhuvrata P,
    3. Still M,
    4. Barron-Millar E,
    5. Nabi G,
    6. Omar MI
    . Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Incontinence Group, ed. Cochrane Database Syst Rev 2023;5:CD003781.
    OpenUrlPubMed
  12. 12.↵
    1. Yeowell G,
    2. Smith P,
    3. Nazir J,
    4. Hakimi Z,
    5. Siddiqui E,
    6. Fatoye F
    . Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 2018;8:e021889.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Kennelly MJ
    . A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol 2010;12:12–9.
    OpenUrlPubMed
  14. 14.↵
    1. Wani MM,
    2. Sheikh MI,
    3. Bhat T,
    4. Bhat Z,
    5. Bhat A
    . Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: a literary review. Curr Urol 2021;15:153–60.
    OpenUrlPubMed
  15. 15.↵
    1. Staskin D,
    2. Frankel J,
    3. Varano S,
    4. Shortino D,
    5. Jankowich R,
    6. Mudd PN
    . International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of Vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 2020;204:316–24.
    OpenUrlPubMed
  16. 16.↵
    1. Kinjo M,
    2. Masuda K,
    3. Nakamura Y,
    4. Miyakawa J,
    5. Tambo M,
    6. Fukuhara H
    . Comparison of Mirabegron and Vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology 2023;175:67–73.
    OpenUrlPubMed
  17. 17.↵
    1. Herschorn S,
    2. Chapple CR,
    3. Abrams P,
    4. et al
    . Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 2017;120:562–75.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Overby Z,
    2. Persons RK,
    3. Carrillo MJ
    . Clinical inquiries. What is the best nonsurgical therapy for pelvic organ prolapse? J Fam Pract 2014;63:471–479.
    OpenUrlPubMed
  19. 19.↵
    1. Hsieh MF,
    2. Tsai HW,
    3. Liou WS,
    4. et al
    . Long-term compliance of vaginal pessaries: does stress urinary incontinence matter? Medicine (Baltimore) 2019;98:e15063.
    OpenUrlPubMed
  20. 20.↵
    1. Malinauskas AP,
    2. Bressan EFM,
    3. de Melo A,
    4. Brasil CA,
    5. Lordêlo P,
    6. Torelli L
    . Efficacy of pelvic floor physiotherapy intervention for stress urinary incontinence in postmenopausal women: systematic review. Arch Gynecol Obstet 2022;308:13–24. Published online July 13.
    OpenUrlPubMed
  21. 21.↵
    1. Todhunter-Brown A,
    2. Hazelton C,
    3. Campbell P,
    4. Elders A,
    5. Hagen S,
    6. McClurg D
    . Conservative interventions for treating urinary incontinence in women: an overview of Cochrane systematic reviews. Cochrane Incontinence Group, ed. Cochrane Database Syst Rev 2022;9:CD012337.
    OpenUrlPubMed
  22. 22.↵
    1. Yang N,
    2. Ge X,
    3. Ye J,
    4. et al
    . Efficacy of acupuncture for urinary incontinence in middle-aged and elderly women: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2021;257:138–43.
    OpenUrlPubMed
  23. 23.↵
    1. Kannan P,
    2. Bello UM
    . Efficacy of various forms of acupuncture for the treatment of urinary incontinence in women: a systematic review and meta-analysis. Explore (NY) 2023;19:26–35.
    OpenUrlPubMed
  24. 24.↵
    1. Bardsley A
    . An overview of urinary incontinence. Br J Nurs Mark Nurs 2016;25:S14–S21.
    OpenUrl
  25. 25.↵
    1. Lerner LB,
    2. McVary KT,
    3. Barry MJ,
    4. et al
    . Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I—initial work-up and medical management. J Urol 2021;206:806–17.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Teunissen TAM,
    2. de Jonge A,
    3. van Weel C,
    4. Lagro-Janssen ALM
    . Treating urinary incontinence in the elderly—conservative measures that work: a systematic review. J Fam Pract 2004;53:25–30, 32.
    OpenUrlPubMedWeb of Science
  27. 27.↵
    1. Verhamme KMC,
    2. Sturkenboom MCJM,
    3. Stricker BHC,
    4. Bosch R
    . Drug-induced urinary retention: incidence, management and prevention. Drug Saf 2008;31:373–88.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Ginsberg DA,
    2. Boone TB,
    3. Cameron AP,
    4. et al
    . The AUA/SUFU Guideline on adult neurogenic lower urinary tract dysfunction: diagnosis and evaluation. J Urol 2021;206:1097–105.
    OpenUrlPubMed
  29. 29.↵
    Self-catheterization (clean intermittent catheterization): how to. Cleveland Clinic. Accessed March 4, 2023. Available at: https://my.clevelandclinic.org/health/treatments/15434-clean-intermittent-catheterization.
  30. 30.↵
    1. Campeau L,
    2. Shamout S,
    3. Baverstock RJ,
    4. et al
    . Canadian Urological Association best practice report: catheter use. Can Urol Assoc J 2020;14:E281–E289.
    OpenUrlPubMed
  31. 31.↵
    1. Grigoriadis T,
    2. Kalantzis C,
    3. Zacharakis D,
    4. et al
    . Platelet-rich plasma for the treatment of stress urinary incontinence—a randomized trial. Urogynecology (Phila) 2024;30:42–9.
    OpenUrlPubMed
  32. 32.
    1. Burgio KL,
    2. Locher JL,
    3. Goode PS,
    4. et al
    . Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995–2000.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.
    1. Liu P,
    2. Li Y,
    3. Shi B,
    4. Zhang Q,
    5. Guo H
    . Comparison of different types of therapy for overactive bladder: a systematic review and network meta-analysis. Front Med (Lausanne) 2022;9:1014291.
    OpenUrlPubMed
  34. 34.
    1. Finazzi-Agrò E,
    2. Petta F,
    3. Sciobica F,
    4. Pasqualetti P,
    5. Musco S,
    6. Bove P
    . Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 2010;184:2001–6.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.
    1. Lin YH,
    2. Hsieh WC,
    3. Huang L,
    4. Liang CC
    . Effect of non-ablative laser treatment on overactive bladder symptoms, urinary incontinence and sexual function in women with urodynamic stress incontinence. Taiwan J Obstet Gynecol 2017;56:815–20.
    OpenUrlPubMed
  36. 36.
    1. Seki AS,
    2. Bianchi-Ferraro AMHM,
    3. Fonseca ESM,
    4. Sartori MGF,
    5. Girão MJBC,
    6. Jarmy-Di Bella ZIK
    . CO2 Laser and radiofrequency compared to a sham control group in treatment of stress urinary incontinence (LARF study arm 3). A randomized controlled trial. Int Urogynecol J 2022;33:3535–42.
    OpenUrlPubMed
  37. 37.
    1. Oefelein MG
    . Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011;34:733–54.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.
    Myrbetriq [Drug Label]. Published online April 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202611s011lbl.pdf.
  39. 39.
    Gemtesa [Drug Label]. Published online December 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213006s000lbl.pdf.
  40. 40.
    1. Castro RA,
    2. Arruda RM,
    3. Zanetti MRD,
    4. Santos PD,
    5. Sartori MGF,
    6. Girão MJBC
    . Single-blind, randomized, controlled trial of pelvic floor muscle training, electrical stimulation, vaginal cones, and no active treatment in the management of stress urinary incontinence. Clinics (Sao Paulo) 2008;63:465–72.
    OpenUrlPubMed
  41. 41.
    1. Aksac B,
    2. Aki S,
    3. Karan A,
    4. Yalcin O,
    5. Isikoglu M,
    6. Eskiyurt N
    . Biofeedback and pelvic floor exercises for the rehabilitation of urinary stress incontinence. Gynecol Obstet Invest 2003;56:23–7.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.
    1. Liu Z,
    2. Liu Y,
    3. Xu H,
    4. et al
    . Effect of electroacupuncture on urinary leakage among women with stress urinary incontinence: a randomized clinical trial. JAMA 2017;317:2493–501.
    OpenUrlCrossRefPubMed
  43. 43.
    1. Narayan P,
    2. Tunuguntla HSGR
    . Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia. Rev Urol 2005;7 Suppl 4:S42–48.
    OpenUrl
  44. 44.
    1. Belayneh M,
    2. Korownyk C
    . Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers. Can Fam Physician 2016;62:e523.
    OpenUrlFREE Full Text
  45. 45.
    1. Dimitropoulos K,
    2. Gravas S
    . Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol 2016;8:19–28.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords